Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
CONTEXT: Women with inherited BRCA1/2 mutations are at high risk for breast cancer, which mammography often misses. Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans. OBJECTIVE: To evaluate the cost-effectiveness of screening BRCA1/2 mutation carriers with mammography plus breast MRI compared with mammography alone. DESIGN, SETTING, AND PATIENTS: A computer model that simulates the life histories of individual BRCA1/2 mutation carriers, incorporating the effects of mammographic and MRI screening was used. The accuracy of mammography and breast MRI was estimated from published data in high-risk women. Breast cancer survival in the absence of screening was based on the Surveillance, Epidemiology and End Results database of breast cancer patients diagnosed in the prescreening period (1975-1981), adjusted for the current use of adjuvant therapy. Utilization rates and costs of diagnostic and treatment interventions were based on a combination of published literature and Medicare payments for 2005. MAIN OUTCOME MEASURES: The survival benefit, incremental costs, and cost-effectiveness of MRI screening strategies, which varied by ages of starting and stopping MRI screening, were computed separately for BRCA1 and BRCA2 mutation carriers. RESULTS: Screening strategies that incorporate annual MRI as well as annual mammography have a cost per quality-adjusted life-year (QALY) gained ranging from less than 45,000 dollars to more than 700,000 dollars, depending on the ages selected for MRI screening and the specific BRCA mutation. Relative to screening with mammography alone, the cost per QALY gained by adding MRI from ages 35 to 54 years is 55,420 dollars for BRCA1 mutation carriers, 130,695 dollars for BRCA2 mutation carriers, and 98,454 dollars for BRCA2 mutation carriers who have mammographically dense breasts. CONCLUSIONS: Breast MRI screening is more cost-effective for BRCA1 than BRCA2 mutation carriers. The cost-effectiveness of adding MRI to mammography varies greatly by age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 2×
“The effect of a background rate of prophylactic bilateral salpingo-oophorectomy (BSO) was assumed to be incorporated into baseline breast cancer incidence rates.(1) Women who had ovarian cancer treated with BSO before menopause were assigned a subsequent 50% reduction in breast cancer risk.”
BackgroundThe Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening
Pisano, E. D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J. K., Acharyya, S., Conant, E. F., Fajardo, L. L., Bassett, L., D'Orsi, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052911 · Cited by 1,940
Kolb, T. M., Lichy, J., & Newhouse, J. H. (2002) · Radiology · doi:10.1148/radiol.2251011667 · Cited by 1,718
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
The Beaver Dam Health Outcomes study: Initial Catalog of Health-state Quality Factors
Fryback, D. G., Dasbach, E. J., Klein, R., Klein, B. E. K., Dorn, N., Peterson, K., & Martin, P. A. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300202 · Cited by 733
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Kuhl, C. K., Schmutzler, R. K., Leutner, C. C., Kempe, A., Wardelmann, E., Hocke, A., Maringa, M., Pfeifer, U., Krebs, D., & Schild, H. H. (2000) · Radiology · doi:10.1148/radiology.215.1.r00ap01267 · Cited by 538
Clinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer
Boyd, J. (2000) · JAMA · doi:10.1001/jama.283.17.2260 · Cited by 536
Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening
Pisano, E. D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J. K., Acharyya, S., Conant, E. F., Fajardo, L. L., Bassett, L., D???Orsi, C., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201894.94616.71 · Cited by 482
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1
Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351901 · Cited by 423
Screening women at high risk for breast cancer with mammography and magnetic resonance imaging
Lehman, C. D., Blume, J. D., Weatherall, P., Thickman, D., Hylton, N., Warner, E., Pisano, E., Schnitt, S. J., Gatsonis, C., Schnall, M., et al. (2005) · Cancer · doi:10.1002/cncr.20971 · Cited by 401
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201966.23445.91 · Cited by 386
Self-citationRe: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Goffin, J., Chappuis, P. O., Wong, N., & Foulkes, W. D. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1754 · Cited by 284
Pierce, L. J., Strawderman, M., Narod, S. A., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L. J., Nixon, A., Garber, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3360 · Cited by 268
Salzmann, P., Kerlikowske, K., & Phillips, K. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00001 · Cited by 247
First experiences in screening women at high risk for breast cancer with MR imaging
Tilanus-Linthorst, M. M. A., Obdeijn, I. M. M., Bartels, K. C. M., de Koning, H. J., & Oudkerk, M. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006480106487 · Cited by 216
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
David, Y. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 200
Tilanus‐Linthorst, M., Verhoog, L., Obdeijn, I., Bartels, K., Menke‐Pluymers, M., Eggermont, A., Klijn, J., Meijers‐Heijboer, H., van der Kwast, T., & Brekelmans, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10666 · Cited by 195
The development of interval breast malignancies in patients with BRCA mutations
Komenaka, I. K., Ditkoff, B., Joseph, K.-A. P., Russo, D., Gorroochurn, P., Ward, M., Horowitz, E., El-Tamer, M. B., & Schnabel, F. R. (2004) · Cancer · doi:10.1002/cncr.20221 · Cited by 155
Grann, V. R., Jacobson, J. S., Thomason, D., Hershman, D. L., Heitjan, D. F., & Neugut, A. I. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.101 · Cited by 154
Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis
Weitzel, J. N. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.12.1323 · Cited by 150
Robson, M. E., Svahn, T. H., McCormick, B. L., Borgen, P. I., Hudis, C. A., Norton, L., & Offit, K. (2004) · Cancer · doi:10.1002/cncr.20728 · Cited by 126
Wainberg, S., & Husted, J. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1989.13.12 · Cited by 113
Cost Comparison of Mastectomy Versus Breast-Conserving Therapy for Early-Stage Breast Cancer
Barlow, W. E., Taplin, S. H., Yoshida, C. K., Buist, D. S. M., Seger, D., & Brown, M. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.447 · Cited by 108
van Roosmalen, M. S., Verhoef, L. C. G., Stalmeier, P. F. M., Hoogerbrugge, N., & van Daal, W. A. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.035 · Cited by 91
The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
Grann, V. R., Jacobson, J. S., Sundararajan, V., Albert, S. M., Troxel, A. B., & Neugut, A. I. (1999) · PubMed · Cited by 61
Psychosocial aspects of cancer genetics: Women at high risk for breast and ovarian cancer
Kash, K. M., Ortega-Verdejo, K., Dabney, M. K., Holland, J. C., Miller, D. G., & Osborne, M. P. (2000) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(200006)18:4<287::aid-ssu3>3.0.co;2-5 · Cited by 50
Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000
Plevritis, S. K., Sigal, B. M., Salzman, P., Rosenberg, J., & Glynn, P. W. (2006) · JNCI Monographs · doi:10.1093/jncimonographs/lgj012 · Cited by 50
Self-citationEconomic outcomes of breast cancer survivorship: CALGB study 79804
Hensley, M. L., Dowell, J. M., Herndon, J. E., Winer, E. P., Stark, N. N., Weeks, J. C., & Paskett, E. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6497-9 · Cited by 43
Childre, F., & Mock, V. (1998) · AAOHN Journal · doi:10.1177/216507999804600904 · Cited by 31
Is adjuvant therapy for older patients with node (−) early breast cancer cost-effective?
Naeim, A., & Keeler, E. B. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.001 · Cited by 28
Peshkin, B. N., Isaacs, C. J., Finch, C., Kent, S., & Schwartz, M. D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.107 · Cited by 26
Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer
Swisher, E. M. (2003) · Current Treatment Options in Oncology · doi:10.1007/s11864-003-0011-1 · Cited by 4
Cited by
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., Helbich, T., Heywang-Köbrunner, S. H., Kaiser, W. A., Kerin, M. J., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.015 · Cited by 992
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm271 · Cited by 944
Kelly, K. M., Dean, J., Comulada, W. S., & Lee, S.-J. (2010) · European Radiology · doi:10.1007/s00330-009-1588-y · Cited by 497
Current Status of Breast MR Imaging Part 2. Clinical Applications
Kuhl, C. K. (2007) · Radiology · doi:10.1148/radiol.2443051661 · Cited by 377
Metadata
- Authors
- Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., & Garber, A. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-05-24
- Volume
- 295
- Issue
- 20
- Pages
- 2374
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2167077733
- Cited by
- 260
- References
- 47
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.